Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to ...
ArriVent BioPharma has dosed the first patient in a global Phase 3 study that could reshape first-line treatment for a small ...
Chart does not reflect overnight price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback